Hungary · Delayed Price · Currency is HUF Gedeon Richter Earnings Call Transcripts
Fiscal Year 2025
-
2025 ended with strong revenue and profit growth, led by Women's Health and innovative products, despite FX and tax headwinds. Outlook for 2026 is high single-digit growth, with continued investment in R&D and efficiency, and new product launches expected to drive future gains.
-
Q3 2025 saw strong growth in innovative segments but was offset by headwinds in GenMed and CDMO, leading to a temporary revenue slowdown. Free cash flow hit a record high, and full-year Clean EBIT is projected to grow 8%-10%. Gross margin is expected to improve in Q4.
-
Pharma sales grew 10.7% YoY in H1 2025, with clean EBIT up 15% and Women's Health leading segment growth. FX volatility and inventory write-offs impacted cash flow, but guidance for 10% revenue and EBIT growth remains on track.
-
Q1 2025 saw strong revenue and EBIT growth, driven by pharma sales and FX gains, with robust free cash flow and a solid cash position. Four biosimilar launches are planned within 12 months, and the outlook for general medicines and women's health remains positive.
Fiscal Year 2024
-
Double-digit revenue and profit growth in 2024, with all business units contributing and strong free cash flow. 2025 guidance targets 10% growth despite lower milestone income, with cost controls and new product launches supporting outlook.
-
Revenue and net profit grew strongly year-over-year, driven by broad-based segment growth and successful M&A. Free cash flow and EBIT improved, with new product launches and biosimilar filings supporting future outlook. FX volatility and regulatory uncertainties remain key risks.
-
Women's healthcare is being transformed through strategic acquisitions, securing key assets like E4 and Donesta, and building in-house R&D. The business is on track to lead in Europe, with ambitious sales and margin targets, and a robust pipeline in contraception, fertility, and menopause.